Been watching ANI Pharmaceuticals lately and there's actually an interesting story brewing here. The company just reported Q4 2025 earnings back in late February, and honestly the execution has been pretty solid across the board.

What caught my attention first was the earnings track record. ANI has beaten expectations for four straight quarters, averaging a 21% surprise rate. That's the kind of consistency you don't see every day, and it tells you management knows how to deliver. Last quarter they came in 17% above consensus, which is solid.

The real story though is in their product mix. Cortrophin Gel, their ACTH injection, has been absolutely crushing it. We're talking 88% year-over-year growth in preliminary numbers. The consensus estimate for Q4 was around $114 million for this drug alone, and the company actually reported $111.4 million. That kind of uptake across neurology, rheumatology, nephrology and ophthalmology doesn't happen by accident. They've clearly expanded their sales force and built real prescriber adoption.

Now, the ophthalmology portfolio they picked up from Alimera Sciences last year—Iluvien and Yutiq—those are facing some headwinds. Medicare reimbursement challenges and inventory drawdown at physician offices are weighing on sales. Consensus was looking for $18.65 million combined, and they came in at $19.8 million. It's not spectacular but it's holding up.

Generic segment is doing what you'd expect in a competitive market—facing pressure. That said, looking at just one quarter misses the bigger picture. ANI's valuation is actually pretty attractive right now. Trading at 1.98x price-to-sales versus 2.5x for the industry, so there's some room there.

The way I see it, ANI has built real momentum in specialty pharma. Cortrophin is their growth engine, and while the rare disease portfolio is dealing with near-term reimbursement noise, the long-term thesis still holds. They've got manufacturing advantages, disciplined execution, and they're gaining share in higher-margin segments.

Competition exists—AbbVie and Regeneron have their own established products in ophthalmology, and Keenova markets Acthar Gel as a Cortrophin competitor. But ANI seems to be winning on execution and market penetration.

For long-term investors, any significant dip in the stock price could be worth accumulating. The fundamentals are there, the earnings durability is proven, and the growth profile looks reasonable. That's the kind of setup I'm keeping on my radar.